Pembrolizumab for advanced lung cancer: T-cell test
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a drug called pembrolizumab (Keytruda) in people with advanced non-small cell lung cancer who haven't received treatment for metastatic disease. Researchers will also study your T-cells (a type of immune cell) to see if they can predict how well the drug works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer that hasn't been treated with chemotherapy or immunotherapy for the metastatic stage.
- You have a tumor that can be measured on scans (like CT or MRI).
- You have a tumor sample from a past biopsy, or you are willing to have a new biopsy.
- You are able to perform daily activities with little to no help (ECOG 0-1).
- You do not have a known genetic change in your cancer (like EGFR, ALK, ROS1) that can be targeted with a pill.
- You have not had treatment with a drug like pembrolizumab (Keytruda) or other checkpoint inhibitors before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the immunotherapy drug pembrolizumab (Keytruda) can help people with advanced non-small cell lung cancer by boosting the body's own immune cells (T-cells) to fight the cancer. It's for people who have not had any prior cancer treatment.
This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
This trial tests whether combining pembrolizumab (an immune treatment) with a lung ablation procedure can be safer and more effective for advanced non-small cell lung cancer after standard first treatment fails or the cancer comes back. It may help shrink tumors and improve control of the disease.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This trial tests a new combination of drugs (Keytruda with or without chemotherapy) to see if it works better for advanced lung cancer. It's for people who haven't had immunotherapy or chemotherapy for their cancer that has spread.
Hear when a new Non Small Cell Lung Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.